nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-7F18143B·Framework v5.8·Pipeline v0.4·Evaluated 19 Aug 2026·OECD: 3.1 Basic medicine·Subfield: Molecular Biology·Basis: Full text·Type: Laboratory experiment

Nrf2-Deficient Mice Have an Increased Susceptibility to Dextran Sulfate Sodium–Induced Colitis

Tin Oo Khor et al.Tin Oo Khor, Mou-Tuan Huang, Ki Han Kwon et al.·2006·10.1158/0008-5472.can-06-3562 ↗

Primary claim

Nrf2-deficient mice were found to be more susceptible to DSS-induced colitis as shown by the increased severity of colitis following 1 week of oral administration of 1% DSS.

Tentative · the acute phenotype is directionally consistent, but central mechanistic claims materially exceed the pooled evidence
In brief

Nrf2 loss credibly increases acute DSS-colitis susceptibility, but pooled molecular assays leave the proposed inflammatory mechanism unconfirmed.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Inflammatory bowel diseases, chronic inflammatory disorders, have been strongly linked with an increased risk of the development of colorectal cancer. Understanding the etiology of these diseases is pivotal for the improvement of currently available strategies to fight against inflammatory bowel disease, and more importantly, to prevent colorectal cancer. Nuclear factor-erythroid 2-related factor 2 (Nrf2) has been known to be a transcriptional factor which plays a crucial role in cytoprotection against inflammation, as well as oxidative and electrophilic stresses. The aim of this study is to investigate the role of Nrf2 in the regulation of dextran sulfate sodium (DSS)-induced experimental colitis in mice. Nrf2-deficient mice were found to be more susceptible to DSS-induced colitis as shown by the increased severity of colitis following 1 week of oral administration of 1% DSS. The increased severity of colitis in Nrf2(-/-) mice was found to be associated with decreased expression of antioxidant/phase II detoxifying enzymes including heme-oxygenase-1, NAD(P)H-quinone reductase-1, UDP-glucurosyltransferase 1A1, and glutathione S-transferase Mu-1. In addition, proinflammatory mediators/cytokines such as COX-2, inducible nitric oxide, interleukin 1beta, interleukin 6, and tumor necrosis factor alpha were significantly increased in the colonic tissues of Nrf2(-/-) mice compared with their wild-type (Nrf2+/+) counterparts. In summary, we show for the first time that mice lacking Nrf2 are more susceptible to DSS-induced colitis. Our data suggests that Nrf2 could play an important role in protecting intestinal integrity, through regulation of proinflammatory cytokines and induction of phase II detoxifying enzymes.

Key Claims

Primary finding · Tentative

Nrf2-deficient mice were found to be more susceptible to DSS-induced colitis as shown by the increased severity of colitis following 1 week of oral administration of 1% DSS.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

the acute phenotype is directionally consistent, but central mechanistic claims materially exceed the pooled evidence

Abstract; Results, Figures 1–2
Quote verified
Secondary · Tentative

The increased severity of colitis in Nrf2(-/-) mice was found to be associated with decreased expression of antioxidant/phase II detoxifying enzymes including HO-1, NQO1, UGT1A1, and GSTM-1.

pooled molecular samples cannot establish replicate-level differences or a robust association

Abstract; Results, Figure 3
Quote verified
Secondary · Unsupported

Proinflammatory mediators/cytokines such as COX-2, inducible nitric oxide, interleukin 1beta, interleukin 6, and tumor necrosis factor alpha were significantly increased in the colonic tissues of Nrf2(-/-) mice.

claimed statistical significance has no reported test on the pooled molecular profiles

Abstract; Results, Figure 3
Quote verified
Secondary · Tentative

Our data suggests that Nrf2 could play an important role in protecting intestinal integrity, through regulation of proinflammatory cytokines and induction of phase II detoxifying enzymes.

appropriately hedged interpretation rests on descriptive molecular evidence without independent biological replication

Abstract; Discussion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Controlled genetic colitis comparison

Four genotype-by-treatment groups permit direct comparison of DSS responses against untreated controls, with PCR genotyping and an F8 backcross reported.

↳ Materials and Methods, Animal care and treatment

#contribution

Convergent acute disease phenotype

Shorter colon length, histologic injury, rectal bleeding, and nitrotyrosine staining point in the same direction, supporting increased acute colitis susceptibility in Nrf2-deficient mice.

↳ Results, General observation and Histologic assessment; Figures 1–2

#positioning

Relevant mechanistic literature framing

The Discussion places the colitis result alongside prior Nrf2 findings in pulmonary inflammation, sepsis, and asthma and cites HO-1 evidence from another colitis model.

↳ Discussion, citations 9–18

Limitations

#methodological rigour

Pooled assays prevent statistical inference

Figure 3 combines colon tissue from at least three mice per group, so per-animal variability and statistical significance for the molecular endpoints cannot be assessed from the reported data.

↳ Materials and Methods, Western blotting and RNA isolation; Figure 3 legend

#contribution

Molecular significance claims exceed analysis

The Abstract and Discussion describe cytokine and enzyme changes as significant despite no reported statistical testing or quantitative replication for those pooled profiles.

↳ Abstract; Discussion; Figure 3

#positioning

Limitations not traced to conclusions

The Discussion acknowledges mechanistic ambiguity but does not address pooled samples, small groups, descriptive histology, or the distance from acute colitis to cancer prevention.

↳ Discussion, mechanistic paragraphs and conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The clearest evidence is the acute susceptibility phenotype: colon length differs statistically, and histology, bleeding, and nitrotyrosine staining are directionally consistent in Figures 1–2. The proposed mechanism is less secure because Figure 3 pools tissue from multiple mice without replicate-level quantification or reported statistics. That gap weighs heavily because the Abstract and Discussion use language implying significant molecular differences. The prior-work discussion is relevant, but it does not carry these limitations through to the chemoprevention extrapolation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
2.5

The study makes a genuine incremental contribution by linking Nrf2 deficiency to greater DSS-colitis susceptibility. Its molecular explanation is materially weaker because pooled expression profiles are described with statistical certainty not supported by reported analyses.

Abstract; Results, Figures 1–3

proinflammatory mediators/cytokines... were significantly increased

Methodological Rigour
3.0

The four-group knockout design, F8 backcross, genotype confirmation, and untreated controls fit the primary question. Small groups, descriptive histology, and pooled molecular samples without biological-replicate variance introduce meaningful execution uncertainty.

Materials and Methods, Animal care and treatment, Histopathologic examinations, and Western blotting; Figure 3 legend

pooled from colonic tissues of at least three mice

Reporting
3.4

The paper follows a coherent progression from phenotype to histology and molecular interpretation. Precision is reduced by using “significantly” for pooled molecular comparisons lacking reported statistical tests.

Abstract; Results, mRNA and protein expression; Figure 3

were significantly increased in the colonic tissues

Positioning
2.8

The Discussion connects the findings to prior Nrf2 inflammation studies and acknowledges uncertainty about the regulatory mechanism. It does not acknowledge that pooled molecular samples and absent endpoint-level statistics limit the mechanistic claims.

Discussion, paragraphs on Nrf2 inflammatory regulation and conclusion; Figure 3 legend

Future experiments will be necessary to elucidate these complicated networks

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The principal susceptibility finding is internally consistent, but statistical language for the molecular findings exceeds the analysis reported for pooled samples. This limits mechanistic interpretation without overturning the direction of the primary phenotype.

Research ConductClean

Animal procedures were reported as approved by the Rutgers Institutional Animal Care and Use Committee and conducted under NIH guidance. No text-grounded research-conduct concern was identified.

Flags: 1 declared / 5 total

Reference IntegrityClean

18 of 18 checkable references verified

18 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesSmall
CitationsFWCI 6.2
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is demonstrated only in controlled mouse experiments with DSS-induced colitis, with no human or independent confirmation.

From the paper
“The present study also supported the rationale of targeting Nrf2 as an important cancer chemoprevention strategy, particularly in the prevention of colorectal cancer.”

The paper names a real-world use, activating Nrf2 for chemoprevention of colorectal cancer, but does not say who would act on it or in what setting.

Pathway

Drug developers could use Nrf2 as a target for chemopreventive or anti-inflammatory agents against IBD and colorectal cancer.

Barrier

The finding rests on a DSS mouse model of colitis and needs validation in human IBD before Nrf2-targeted interventions can be developed.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

    Zhiyong Wen, Weihua Liu, Xing Li, et al. · 2019 · Basic medicine

    Primary claim

    NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

    Supported
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns

How the rubric works →